(Q50268592)

English

Reduced platelet transfusions and earlier platelet engraftment using alemtuzumab-based conditioning regimen in allogeneic stem cell transplantation.

scientific article published on 16 January 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/26779644

Reduced platelet transfusions and earlier platelet engraftment using alemtuzumab-based conditioning regimen in allogeneic stem cell transplantation. (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/26779644

Andreas Greinacher

8

object named as

Andreas Greinacher

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

author name string

Thomas Neumann

1

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/26779644

Laila Schneidewind

2

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/26779644

Thomas Thiele

3

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/26779644

Meike Schulze

4

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/26779644

Anne F Klenner

5

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/26779644

Christoph Busemann

6

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/26779644

Daniel Pink

7

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/26779644

Gottfried Dölken

9

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/26779644

William H Krüger

10

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/26779644

publication date

16 January 2016

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/26779644

Journal of Cancer Research and Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/26779644

142

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/26779644

5

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/26779644

1091-1097

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/26779644

https://scigraph.springernature.com/pub.10.1007/s00432-016-2114-7

0 references

Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2114-7

21 January 2018

A Novel GVHD-Prophylaxis with Low-Dose Alemtuzumab in Allogeneic Sibling or Unrelated Donor Hematopoetic Cell Transplantation: The Feasibility of Deescalation

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2114-7

21 January 2018

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2114-7

21 January 2018

Mechanism of Platelet Activation and Hypercoagulability by Antithymocyte Globulins (ATG).

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2114-7

21 January 2018

The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2114-7

21 January 2018

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2114-7

21 January 2018

Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survival

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2114-7

21 January 2018

Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2114-7

21 January 2018

Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath).

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2114-7

21 January 2018

Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2114-7

21 January 2018

Serotherapy with thymoglobulin and alemtuzumab differentially influences frequency and function of natural killer cells after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2114-7

21 January 2018

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2114-7

21 January 2018

Alemtuzumab in allogeneic hematopoetic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2114-7

21 January 2018

Dose of prophylactic platelet transfusions and prevention of hemorrhage

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2114-7

21 January 2018

Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2114-7

21 January 2018

A no-prophylaxis platelet-transfusion strategy for hematologic cancers

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2114-7

21 January 2018

Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2114-7

21 January 2018

CAMPATH: from concept to clinic

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2114-7

21 January 2018

Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2114-7

21 January 2018

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution

1 reference

https://pubmed.ncbi.nlm.nih.gov/26779644

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low-dose alemtuzumab vs. standard policy for prevention of graft-versus-host disease in unrelated and related allogeneic stem cell transplantation-a matched pair analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26779644

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhancement of megakaryocytopoiesis by Campath-1G-treated natural killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/26779644

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection

1 reference

https://pubmed.ncbi.nlm.nih.gov/26779644

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin

1 reference

https://pubmed.ncbi.nlm.nih.gov/26779644

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Release, aggregation and lysis of human platelets by antilymphocyte globulin and antiplatelet serum

1 reference

https://pubmed.ncbi.nlm.nih.gov/26779644

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of bone marrow T lymphocytes treated with CAMPATH 1G on megakaryocyte colony formation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26779644

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of Campath and Thymoglobulin as part of the conditioning before allogeneic hematopoietic stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/26779644

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of antithymocyte globulin and other immune reactants on human platelets

1 reference

https://pubmed.ncbi.nlm.nih.gov/26779644

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/26779644

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-human thymocyte globulin (ATG) for prophylaxis and treatment of graft-versus-host disease in recipients of allogeneic marrow grafts

1 reference

https://pubmed.ncbi.nlm.nih.gov/26779644

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults

1 reference

https://pubmed.ncbi.nlm.nih.gov/26779644

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized study of the prevention of acute graft-versus-host disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/26779644

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00432-016-2114-7

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/26779644

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/26779644

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50268592&oldid=1450547342"